Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex v... Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. Mehr anzeigen
WOBURN, Mass., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today...
Completed Pre-Biologics License Application (BLA) meeting with the U.S. Food and Drug Administration (FDA) and remain on track to submit a BLA for RP1 plus nivolumab in anti-PD1 failed melanoma...
Oral presentation highlighting IGNYTE primary analysis data shows anti-tumor activity across all subgroups with injected and non-injected lesions responding with similar frequency, depth...
WOBURN, Mass., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 3.385 | 29.5762341634 | 11.445 | 15.55 | 10.575 | 852901 | 10.91223259 | CS |
| 4 | 2.84 | 23.6864053378 | 11.99 | 15.55 | 10.575 | 519579 | 11.58051064 | CS |
| 12 | 3.77 | 34.0867992767 | 11.06 | 15.55 | 9.94 | 672139 | 11.26064216 | CS |
| 26 | 9.32 | 169.147005445 | 5.51 | 15.55 | 4.92 | 896242 | 9.46836846 | CS |
| 52 | 4.25 | 40.1701323251 | 10.58 | 15.55 | 4.92 | 1162542 | 8.48261818 | CS |
| 156 | -20.105 | -57.5497352226 | 34.935 | 35.055 | 4.92 | 700114 | 13.35792969 | CS |
| 260 | 1.1 | 8.01165331391 | 13.73 | 54.85 | 4.92 | 539872 | 17.88945806 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
